Y-mAbs Reports Fourth Quarter 2024 Financial Results

March 4 (Reuters) - Y-mAbs Therapeutics YMAB.O:

• Y-MABS THERAPEUTICS Q4 PRODUCT REVENUE USD 26.5 MILLION

• 2025 ANTICIPATED TOTAL REVENUES EXPECTED TO BE BETWEEN $75 MILLION AND $90 MILLION

• : CASH AND CASH EQUIVALENTS ANTICIPATED TO BE SUFFICIENT TO FUND OPERATIONS AS CURRENTLY PLANNED INTO 2027

• OUTLOOK Q1 REVENUES EXPECTED TO BE BETWEEN $18 MILLION AND $21 MILLION

• Q1 REVENUE VIEW $24.4 MILLION -- LSEG IBES DATA

• FY2025 REVENUE VIEW $104.5 MILLION -- LSEG IBES DATA

• : QTRLY LOSS PER SHARE $0.15

• Q4 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $27.3 MILLION -- LSEG IBES DATA

Further company coverage: YMAB.O